Aclidinium bromide
| File:Aclidinium bromide structure.png | |
| Systematic (IUPAC) name | |
|---|---|
|
[(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide | |
| Clinical data | |
| Routes of administration | Inhalational |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 320345-99-1 |
| ATC code | none |
| PubChem | CID 11519741 |
| Chemical data | |
| Formula | C26H30BrNO4S2 |
| Molar mass | 564.555 g/mol[[Script error: No such module "String".]] |
Aclidinium bromide (INN) is a novel, long-acting, inhaled muscarinic antagonist currently being developed as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[1] Preclinically, aclidinium showed potent antagonism of human muscarinic receptors, with a long residence time at M3 receptors and a shorter residence time at M2 receptors, indicating the potential to provide sustained bronchodilation.[2] Aclidinium is rapidly hydrolysed in human plasma, unlike other currently available antimuscarinics including tiotropium.[2][3] This results in very low and transient systemic exposure, suggesting a reduced potential for class-related systemic side effects in the clinical setting.[2][3]
Early clinical studies in healthy subjects have confirmed the low systemic bioavailability and favourable safety profile of single and multiple doses of aclidinium.[4][5] In a subsequent Phase IIb study, which included 464 patients with moderate to severe COPD, aclidinium displayed long-lasting bronchodilatory activity and was well tolerated.[6]
Aclidinium is delivered via a novel, multidose dry powder inhaler, the Genuair inhaler.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ Gavaldà A, Miralpeix M, Ramos I; et al. (2009). "Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile". J Pharmacol Exp Ther. Epub ahead of print.
- ↑ 2.0 2.1 2.2 Gavaldà A, Miralpeix M, Ramos I (2007). "Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance". Eur Respir J. 30 (suppl 51): 209S–210S.
- ↑ 3.0 3.1 Gavaldà A, Sentellas S, Alberti J; et al. (2008). "Aclidinium bromide, a novel long-acting anticholinergic, is rapidly inactivated in plasma". Am J Respir Crit Care Med. 177: A–654.
- ↑ Janset JM, Lamarca R, Garcia Gil E, Ferrer P. (2009). "Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects". Int J Clin Pharmacol Ther. 47: 460–468.
- ↑ Janset JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M. (2009). "Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants". J Clin Pharmacol. Epub ahead of print.
- ↑ Chanez P, Burge PS, Dahl R; et al. (2009). "Aclidinium bromide provides long-acting bronchodilation in patients with COPD". Pulm Pharmacol Ther. Epub ahead of print.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Muscarinic antagonists
- Bromides
- Quaternary ammonium compounds
- Quinuclidines
- Thiophenes
- Phenol ethers
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
